MCD
MCID: KPS004
MIFTS: 77

Kaposi Sarcoma (MCD)

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Kaposi Sarcoma

MalaCards integrated aliases for Kaposi Sarcoma:

Name: Kaposi Sarcoma 58 12 77 54 60 38 56 44 15 74
Kaposi's Sarcoma 12 54 30 15 17
Kaposi Sarcoma, Susceptibility to 58 13 6
Angiofollicular Ganglionic Hyperplasia 60 74
Kaposi's Sarcoma of Soft Tissue 12 74
Kaposi's Sarcoma of Palate 12 74
Kaposi's Sarcoma of Lung 12 74
Multiple Idiopathic Pigmented Hemangiosarcoma, Susceptibility to 58
Multiple Idiopathic Pigmented Hemangiosarcoma 58
Kaposi's Sarcoma of Central Nervous System 12
Kaposi's Sarcoma of Gastrointestinal Sites 12
Multicentric Giant Lymph Node Hyperplasia 60
African Lymphadenopathic Kaposi's Sarcoma 12
Central Nervous System Kaposi's Sarcoma 12
Kaposi's Sarcoma-Associated Herpesvirus 12
Kaposi's Sarcoma of the Gallbladder 12
Sarcoma, Kaposi, Susceptibility to 41
Angiofollicular Lymph Hyperplasia 60
Lymphadenopathic Kaposi's Sarcoma 12
Multi-Centric Castleman's Disease 74
Kaposi's Sarcoma of Soft Tissues 12
Kaposi's Sarcoma of the Prostate 12
Kaposi's Sarcoma of Conjunctiva 12
Kaposi's Sarcoma of Lymph Nodes 12
Non Aids Related Kaposi Sarcoma 54
Non-Aids-Related Kaposi Sarcoma 74
Multicentric Castleman Disease 60
Conjunctival Kaposi's Sarcoma 12
Kaposi's Sarcoma of Esophagus 12
Gallbladder Kaposi's Sarcoma 12
Soft Tissue Kaposi's Sarcoma 12
Mediterranean Kaposi Sarcoma 54
Esophageal Kaposi's Sarcoma 12
Intestinal Kaposi's Sarcoma 12
Kaposi's Sarcoma of the Cns 12
Lymph Node Kaposi's Sarcoma 12
Cutaneous Kaposi's Sarcoma 12
Kaposi's Sarcoma of Cornea 12
Pulmonary Kaposi's Sarcoma 12
Kaposi Sarcoma Herpesvirus 54
Kaposi's Sarcoma of Heart 12
Kaposi's Sarcoma of Penis 12
Prostate Kaposi's Sarcoma 12
Angiolymphoid Hyperplasia 74
Cardiac Kaposi's Sarcoma 12
Corneal Kaposi's Sarcoma 12
Gastric Kaposi's Sarcoma 12
Kaposi's Sarcoma of Anus 12
Kaposi's Sarcoma of Skin 12
Palate Kaposi's Sarcoma 12
Kaposi's Sarcoma, Lung 12
Kaposi's Sarcoma, Skin 12
Penis Kaposi's Sarcoma 12
Anal Kaposi's Sarcoma 12
Human Herpesvirus 8 54
Castleman Disease 60
Sarcoma, Kaposi 45
Hhv8 54
Kshv 54
Mcd 60

Characteristics:

Orphanet epidemiological data:

60
kaposi sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;
castleman disease
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
kaposi sarcoma:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Kaposi Sarcoma

NIH Rare Diseases : 54 Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. These lesions may look bad, but they usually cause no symptoms. However, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. Kaposi sarcoma is caused by infection with a virus called the Kaposi sarcoma associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8). Kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-Saharan indigenous Africans), iatrogenic (associated with immunosuppressive drug therapy) and AIDS-associated (epidemic KS). Options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy (immunotherapy). The main aim is to restore immunity.

MalaCards based summary : Kaposi Sarcoma, also known as kaposi's sarcoma, is related to sarcoma and acquired immunodeficiency syndrome, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Kaposi sarcoma-associated herpesvirus infection and Viral carcinogenesis. The drugs Taxol and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are recurrent herpes and neoplasm of the skin

Disease Ontology : 12 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in_formation_of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

OMIM : 58 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000). Suthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD). (148000)

MedlinePlus : 44 Kaposi sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. They are made of cancer cells, blood vessels, and blood cells. KS is caused by infection with human herpesvirus-8 (HHV-8). Most people infected with HHV-8 don't get KS. It usually happens in People with weak immune systems, due to HIV/AIDS, drugs taken after an organ transplant, or another disease Older men of Jewish or Mediterranean descent Young men in Africa The skin lesions may not cause symptoms. But they can spread to other parts of the body, especially in people with HIV/AIDS. If they spread to the digestive tract or lungs, they can cause bleeding. Lesions on the lungs can also make it hard to breathe. Treatment depends on where the lesions are and how bad they are. Options include radiation therapy, surgery, chemotherapy, and biologic therapy. People with HIV/AIDS also take HIV/AIDS medicines. NIH: National Cancer Institute

Wikipedia : 77 Kaposi''s sarcoma (KS) is a type of cancer that can form masses in the skin, lymph nodes, or other... more...

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 518)
# Related Disease Score Top Affiliating Genes
1 sarcoma 31.9 TP53 PDGFB KDR IL6ST IL6 ICAM1
2 acquired immunodeficiency syndrome 31.4 IFNA1 IFNA2 IL6 TP53
3 lymphangioma 31.1 IFNA2 KDR VEGFA
4 myeloma, multiple 30.7 FGF2 IFNA1 IL6 TP53 VEGFA
5 poems syndrome 30.6 VEGFA IL6 FGF2
6 pericardial effusion 30.5 FGF2 IL6 VEGFA
7 nervous system disease 30.5 IFNB1 IL6 TP53 VEGFA
8 rheumatoid arthritis 30.4 CXCL1 ICAM1 IL6 IL6ST VEGFA
9 multiple sclerosis 30.4 ICAM1 IFNA1 IFNB1 IL6
10 retinal vascular disease 30.3 ICAM1 KDR VEGFA
11 relapsing-remitting multiple sclerosis 30.3 ICAM1 IFNA1 IFNB1
12 hepatitis c 30.1 IFNA1 IFNA2 IFNB1 IRF7
13 renal cell carcinoma, nonpapillary 30.1 VEGFA KDR IFNA2 IFNA1 FGF2
14 hepatocellular carcinoma 29.9 FGF2 ICAM1 IFNA1 IL6 KDR TP53
15 glioma 29.7 VEGFA TP53 PDGFB KDR FGF2 CDK6
16 endemic kaposi sarcoma 12.5
17 colon kaposi sarcoma 12.3
18 pediatric castleman disease 12.3
19 immunodeficiency 16 12.1
20 human herpesvirus 8 12.1
21 malonyl-coa decarboxylase deficiency 12.0
22 macular dystrophy, corneal 11.9
23 multiple carboxylase deficiency 11.9
24 metaphyseal chondrodysplasia, schmid type 11.8
25 holocarboxylase synthetase deficiency 11.8
26 biotinidase deficiency 11.7
27 focal segmental glomerulosclerosis 11.5
28 lipoid nephrosis 11.5
29 littoral cell angioma of the spleen 11.3
30 rectum kaposi's sarcoma 11.3
31 c1q nephropathy 11.2
32 corneal dystrophy, meesmann 11.0
33 metaphyseal dysplasia, spahr type 11.0
34 cortical malformations, occipital 11.0
35 microlissencephaly 11.0
36 spindle cell sarcoma 10.8
37 lymphoma 10.7
38 castleman disease 10.6
39 multicentric castleman disease 10.6
40 primary effusion lymphoma 10.5
41 macular retinal edema 10.5 VEGFA IL6 ICAM1
42 lymphomatoid granulomatosis 10.5 IFNA1 IFNA2
43 arteriovenous malformations of the brain 10.5 IL6 KDR VEGFA
44 radiation proctitis 10.5 FGF2 KDR VEGFA
45 leukostasis 10.5 VEGFA KDR ICAM1
46 angiomatous meningioma 10.5 VEGFA KDR FGF2
47 oral erosive lichen 10.5 IFNA1 IFNB1
48 parasitic protozoa infectious disease 10.5 ICAM1 IL6 KDR
49 vascular cancer 10.4 FGF2 KDR VEGFA
50 human immunodeficiency virus infectious disease 10.4

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Human phenotypes related to Kaposi Sarcoma:

33 60 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 recurrent herpes 33 obligate (100%) HP:0005353
2 neoplasm of the skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0008069
3 hypermelanotic macule 60 33 hallmark (90%) Very frequent (99-80%) HP:0001034
4 abnormality of the lower limb 60 33 hallmark (90%) Very frequent (99-80%) HP:0002814
5 immunodeficiency 60 33 frequent (33%) Frequent (79-30%) HP:0002721
6 abnormality of the spleen 60 33 frequent (33%) Frequent (79-30%) HP:0001743
7 papule 60 33 frequent (33%) Frequent (79-30%) HP:0200034
8 abnormality of the gastrointestinal tract 60 33 frequent (33%) Frequent (79-30%) HP:0011024
9 encephalopathy 60 33 frequent (33%) Frequent (79-30%) HP:0001298
10 abnormal retinal morphology 60 33 frequent (33%) Frequent (79-30%) HP:0000479
11 skin nodule 60 33 frequent (33%) Frequent (79-30%) HP:0200036
12 hemangioma 60 33 frequent (33%) Frequent (79-30%) HP:0001028
13 lymphoproliferative disorder 60 33 frequent (33%) Frequent (79-30%) HP:0005523
14 generalized lymphadenopathy 60 33 frequent (33%) Frequent (79-30%) HP:0008940
15 fever 60 33 occasional (7.5%) Occasional (29-5%) HP:0001945
16 fatigue 60 33 occasional (7.5%) Occasional (29-5%) HP:0012378
17 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
18 lymphedema 60 33 occasional (7.5%) Occasional (29-5%) HP:0001004
19 diarrhea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002014
20 skin rash 60 33 occasional (7.5%) Occasional (29-5%) HP:0000988
21 venous insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0005293
22 abnormality of the liver 60 33 occasional (7.5%) Occasional (29-5%) HP:0001392
23 skin plaque 60 33 occasional (7.5%) Occasional (29-5%) HP:0200035
24 abnormal lung morphology 33 occasional (7.5%) HP:0002088
25 edema 33 HP:0000969
26 sarcoma 33 HP:0100242
27 macule 60 Very frequent (99-80%)
28 abnormality of lung morphology 60 Occasional (29-5%)
29 susceptibility to herpesvirus 60 Obligate (100%)
30 neoplasm by anatomical site 60 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM:

58
Oncology:
kaposi sarcoma

Misc:
rarely familial

Skin:
red-purple nodules, plaques, and macules
limb edema

Clinical features from OMIM:

148000

UMLS symptoms related to Kaposi Sarcoma:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Kaposi Sarcoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 CDK6 FGF2 ICAM1 IFNB1 IL6 IL6ST
2 immune system MP:0005387 10.15 CCR8 CDK6 ICAM1 IFNB1 IL6 IL6ST
3 integument MP:0010771 9.92 ICAM1 IL6 IL6ST KDR PDGFB SLC7A11
4 liver/biliary system MP:0005370 9.8 CDK6 IL6 IL6ST KDR PDGFB TP53
5 muscle MP:0005369 9.76 CDK6 FGF2 ICAM1 IL6 KDR PDGFB
6 neoplasm MP:0002006 9.61 CDK6 FGF2 ICAM1 IFNB1 IL6 IL6ST
7 vision/eye MP:0005391 9.28 FGF2 ICAM1 IL6 IL6ST KDR PDGFB

Drugs & Therapeutics for Kaposi Sarcoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Taxol 19 50 PACLITAXEL Bristol-Myers Squibb August 1997

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
2
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
3
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
5
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
6
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
7
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
8
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
9
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
10
Emtricitabine Approved, Investigational Phase 4,Phase 3,Not Applicable 143491-57-0 60877
11
Valganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 175865-60-8 64147
12
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
13
Tenofovir Experimental, Investigational Phase 4,Phase 3,Not Applicable 147127-20-6 464205
14 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Not Applicable
20 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
22 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Not Applicable
23 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
24
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
26 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Not Applicable
28 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
29 Atazanavir Sulfate Phase 4,Phase 3
30
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 5281106 54677470
31
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
32
Zidovudine Approved Phase 2, Phase 3,Phase 3,Phase 1 30516-87-1 35370
33
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 441300 65140
34
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
35
Daunorubicin Approved Phase 3,Phase 1 20830-81-3 30323
36
Aldesleukin Approved Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
37
tannic acid Approved Phase 3 1401-55-4
38
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
39
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
40
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
41
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
42 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
43 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
44 Antimitotic Agents Phase 3,Phase 2,Phase 1
45 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
46 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
47 Analgesics Phase 3,Phase 1,Phase 2,Not Applicable
48 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Not Applicable
49 Analgesics, Non-Narcotic Phase 3,Phase 1,Phase 2,Not Applicable
50 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 190)
# Name Status NCT ID Phase Drugs
1 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
2 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
3 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
4 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
5 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
6 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
7 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
8 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
9 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma Active, not recruiting NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
10 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
11 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
12 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
13 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3 IM862
14 A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
15 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
16 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
17 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Active, not recruiting NCT01435018 Phase 3 Coformulated EFV/FTC/TDF;Etoposide;Bleomycin and Vincristine (BV);Paclitaxel (PTX)
18 Mirasol Evaluation of Reduction in Infections Trial Not yet recruiting NCT03737669 Phase 3
19 PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) Completed NCT01099579 Phase 3 Atazanavir powder;Ritonavir oral solution;Atazanavir capsules;Ritonavir capsules
20 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
21 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
22 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
23 Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Recruiting NCT03092817 Phase 3 Dexamethasone
24 Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma Unknown status NCT00003419 Phase 2
25 Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer Unknown status NCT00622466 Phase 2 paclitaxel;sorafenib tosylate
26 Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Recruiting NCT03077451 Phase 2 Nelfinavir Mesylate
27 Pomalidomide for Kaposi Sarcoma in People With or Without HIV Active, not recruiting NCT01495598 Phase 1, Phase 2 Pomalidomide
28 A Study of Selumetinib in Patients With Kaposi's Sarcoma Terminated NCT01752569 Phase 1, Phase 2 Selumetinib
29 Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma Completed NCT01067690 Phase 2 Indinavir in association with Vinblastina +/- Bleomicina
30 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity Completed NCT01296815 Phase 2 Bevacizumab
31 PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma Terminated NCT00686842 Phase 1, Phase 2 VEGF inhibitor PTC299
32 Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) Recruiting NCT03219671 Phase 2 Nivolumab;Ipilimumab
33 sEphB4-HSA in Treating Patients With Kaposi Sarcoma Recruiting NCT02799485 Phase 2
34 Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma Active, not recruiting NCT03296553 Phase 2 Valganciclovir;Antiretroviral Combinations
35 Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir Completed NCT00362310 Phase 2 indinavir
36 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT01057121 Phase 1, Phase 2 Lenalidomide
37 Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma Withdrawn NCT02229981 Phase 1, Phase 2 ABC294640
38 A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma Terminated NCT01412515 Phase 2 everolimus
39 Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
40 Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00064142 Phase 2 halofuginone hydrobromide
41 Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection Not yet recruiting NCT03601806 Phase 2 Pomalidomide
42 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma Completed NCT02029430 Phase 2 aldoxorubicin
43 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients Completed NCT00055237 Phase 2
44 Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma Withdrawn NCT00521092 Phase 2 sunitinib malate
45 A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma Terminated NCT00020683 Phase 2 incyclinide;incyclinide
46 Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma Withdrawn NCT02137564 Phase 2 gamma secretase inhibitor PF-03084014
47 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT Completed NCT02201420 Phase 2 Tc 99m tilmanocept
48 Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma Completed NCT00295984 Phase 2 nicotine
49 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00090987 Phase 2 imatinib mesylate
50 BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2 rebimastat

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

Genetic tests related to Kaposi Sarcoma:

# Genetic test Affiliating Genes
1 Kaposi's Sarcoma 30

Anatomical Context for Kaposi Sarcoma

MalaCards organs/tissues related to Kaposi Sarcoma:

42
Skin, Lymph Node, Lung, Endothelial, Prostate, B Cells, Kidney

Publications for Kaposi Sarcoma

Articles related to Kaposi Sarcoma:

(show top 50) (show all 3147)
# Title Authors Year
1
Kaposi's sarcoma-associated herpesvirus seropositivity is associated with type 2 diabetes mellitus: A case-control study in Xinjiang, China. ( 30639407 )
2019
2
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 associated lymphoproliferative disorders. ( 30610029 )
2019
3
Pediatric post-transplant hepatic kaposi sarcoma due to donor-derived human herpesvirus 8. ( 30843320 )
2019
4
Fragment-based discovery of a qualified hit targeting the Latency-associated Nuclear Antigen of the oncogenic Kaposi's Sarcoma-associated Herpesvirus/Human Herpesvirus 8. ( 30888817 )
2019
5
KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions. ( 30204240 )
2019
6
Kaposi sarcoma-associated herpes virus (KSHV) latent protein LANA modulates cellular genes associated with epithelial-to-mesenchymal transition. ( 30284629 )
2019
7
Regression of human immunodeficiency virus-associated oral Kaposi sarcoma with combined antiretroviral therapy: A case report and literature review. ( 30552825 )
2019
8
Oral Kaposi Sarcoma. ( 30601874 )
2019
9
Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR-inhibitors: 1997-2016. ( 30613958 )
2019
10
Kaposi sarcoma. ( 30705285 )
2019
11
Kaposi sarcoma. ( 30705286 )
2019
12
Kaposi Sarcoma Masquerading as a Tooth Abscess in a Patient With Human Immunodeficiency Virus. ( 30711137 )
2019
13
Extracellular vesicles from Kaposi Sarcoma-associated herpesvirus lymphoma induce long-term endothelial cell reprogramming. ( 30716130 )
2019
14
Kaposi sarcoma of th e penis in anHIV-negative patient. ( 30785473 )
2019
15
AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. ( 30787130 )
2019
16
Designing a multi-epitope based vaccine to combat Kaposi Sarcoma utilizing immunoinformatics approach. ( 30792446 )
2019
17
Kaposi sarcoma associated with rituximab-based cytotoxic therapy. ( 30854926 )
2019
18
Management of Kaposi Sarcoma after Solid Organ Transplantation: a European Retrospective Study. ( 30902727 )
2019
19
Chylous ascites in disseminated Kaposi sarcoma: an unusual manifestation as immune reconstitution inflammatory syndrome. ( 30904896 )
2019
20
Refractory Thrombotic Thrombocytopenic Purpura in a patient with Kaposi sarcoma. ( 30910619 )
2019
21
Comment on: 'Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma'. ( 30690766 )
2019
22
HACE1, an E3 ubiquitin-protein ligase, Mitigates Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Infection Induced Oxidative Stress by Promoting Nrf2 Activity. ( 30787155 )
2019
23
Docetaxel therapy for classic Kaposi's sarcoma. ( 30790461 )
2019
24
NDRG1 facilitates the replication and persistence of Kaposi's sarcoma-associated herpesvirus by interacting with the DNA polymerase clamp PCNA. ( 30811506 )
2019
25
PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma. ( 30835883 )
2019
26
Development of an ORF45-derived peptide to inhibit the sustained RSK activation and lytic replication of Kaposi's sarcoma-associated herpesvirus. ( 30842327 )
2019
27
Latency-associated nuclear antigen inhibits lytic replication of Kaposi's sarcoma-associated herpesvirus by regulating let-7a/RBPJ signaling. ( 30856484 )
2019
28
In vivo models of oncoproteins encoded by Kaposi's sarcoma-associated herpesvirus. ( 30867309 )
2019
29
Paclitaxel as first or second-line treatment for HIV-negative Kaposi's sarcoma: a retrospective study of 58 patients. ( 30897011 )
2019
30
Arachidonic Acid Derived Lipid Mediators Influence Kaposi's Sarcoma-Associated Herpesvirus Infection and Pathogenesis. ( 30915039 )
2019
31
An endothelial cell line infected by Kaposi's sarcoma-associated herpes virus (KSHV) allows the investigation of Kaposi's sarcoma and the validation of novel viral inhibitors in vitro and in vivo. ( 30610257 )
2019
32
Kaposi's Sarcoma-Associated Herpesvirus LANA-Adjacent Regions with Distinct Functions in Episome Segregation or Maintenance. ( 30626680 )
2019
33
Sirtuin 6 Attenuates Kaposi's Sarcoma-associated herpesvirus (KSHV) Reactivation via Suppressing the Ori-Lyt Activity and Expression of RTA. ( 30651359 )
2019
34
Reduction of Kaposi's sarcoma-associated herpesvirus latency using CRISPR-Cas9 to edit the latency-associated nuclear antigen gene. ( 30651362 )
2019
35
Expression of TLR4 gene is downregulated in acquired immune deficiency syndrome-associated Kaposi's sarcoma. ( 30651761 )
2019
36
Chylothorax in a patient with HIV-related Kaposi's sarcoma. ( 30674495 )
2019
37
Human immunodeficiency virus-negative multicentric Castleman's disease coexistent with Kaposi's sarcoma on 18F-FDG PET/CT: A case report. ( 30680214 )
2019
38
The DNase Activity of KSHV SOX Protein Serves an Important Role in Viral Genome Processing During Lytic Replication. ( 30728255 )
2019
39
Latent infection with Kaposi's sarcoma-associated herpesvirus enhances retrotransposition of long interspersed element-1. ( 30770900 )
2019
40
Ephrin Receptor A4 is a New Kaposi's Sarcoma-Associated Herpesvirus Virus Entry Receptor. ( 30782663 )
2019
41
Kaposi's sarcoma-associated herpesvirus ORF57 protein protects viral transcripts from specific nuclear RNA decay pathways by preventing hMTR4 recruitment. ( 30785952 )
2019
42
Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update. ( 30523621 )
2019
43
Circulating miRNA-375 as a potential novel biomarker for active Kaposi's sarcoma in AIDS patients. ( 30549196 )
2019
44
Antineoplastic effect of 1α,25(OH)2D3 in spheroids from endothelial cells transformed by Kaposi's sarcoma-associated herpesvirus G protein coupled receptor. ( 30308321 )
2019
45
FoxO1 Suppresses Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication and Controls Viral Latency. ( 30404794 )
2019
46
Kaposi Sarcoma in the Era of Rapamycin Remains a Therapeutic Challenge in Organ Transplant Recipients. ( 29527986 )
2018
47
Evolution of Kaposi sarcoma in the past 30A years in a tertiary hospital of the European Mediterranean basin. ( 29934954 )
2018
48
Case of classic Kaposi sarcoma of the penis successfully treated with radiotherapy. ( 29341256 )
2018
49
PD-1 blockade with nivolumab in endemic Kaposi sarcoma. ( 29324995 )
2018
50
Role of Radiotherapy in Mucosal Kaposi Sarcoma. ( 29383006 )
2018

Variations for Kaposi Sarcoma

ClinVar genetic disease variations for Kaposi Sarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 IL6 IL6, -174G-C single nucleotide variant risk factor

Cosmic variations for Kaposi Sarcoma:

9 (show all 29)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6979022 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 0
2 COSM389868 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 0
3 COSM6979014 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 0
4 COSM6959031 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 0
5 COSM6979006 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 0
6 COSM6979021 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 0
7 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 0
8 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 0
9 COSM516 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 0
10 COSM521 KRAS biliary tract,gallbladder,other,hyperplasia c.35G>A p.G12D 12:25245350-25245350 0
11 COSM517 KRAS biliary tract,gallbladder,other,hyperplasia c.34G>A p.G12S 12:25245351-25245351 0
12 COSM6979011 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 0
13 COSM6959034 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 0
14 COSM6979008 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 0
15 COSM6959030 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 0
16 COSM6979007 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 0
17 COSM6979005 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 0
18 COSM6979015 soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 0
19 COSM6979012 soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 0
20 COSM1140136 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 0
21 COSM6979020 soft tissue,lung,sarcoma,NS c.1831+1G>T p.? 19:45353082-45353082 0
22 COSM6979017 soft tissue,lung,sarcoma,NS c.2573C>T p.A858V 9:8404587-8404587 0
23 COSM6979010 soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 0
24 COSM6979009 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 0
25 COSM1154840 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 0
26 COSM6959033 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 0
27 COSM6979016 soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 0
28 COSM6979013 soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 0
29 COSM6959032 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 0

Expression for Kaposi Sarcoma

Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for Kaposi Sarcoma

Pathways related to Kaposi Sarcoma according to KEGG:

38
# Name Kegg Source Accession
1 Kaposi sarcoma-associated herpesvirus infection hsa05167
2 Viral carcinogenesis hsa05203

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 ADA2 CXCL1 FGF2 FGF4 ICAM1 IFNA1
2
Show member pathways
13.9 FGF2 FGF4 IFNA1 IFNA2 IFNB1 IL6
3
Show member pathways
13.88 CCR8 CDK6 CXCL1 FGF2 FGF4 IL6
4
Show member pathways
13.69 CCR8 CXCL1 IFNA1 IFNA2 IFNB1 IL6
5
Show member pathways
13.5 FGF2 FGF4 ICAM1 IFNA1 IFNA2 IFNB1
6
Show member pathways
13.41 CCR8 CXCL1 FGF2 FGF4 IL6 KDR
7
Show member pathways
13.32 IFNA1 IFNA2 IFNB1 IRF7 PDGFB SLC7A11
8
Show member pathways
13.31 CCR8 CXCL1 FGF2 FGF4 IL6 KDR
9
Show member pathways
13.19 CXCL1 IFNA1 IFNA2 IFNB1 IL6 IRF7
10
Show member pathways
13.08 FGF2 FGF4 IL6 KDR PDGFB TP53
11
Show member pathways
13.08 CXCL1 FGF2 FGF4 ICAM1 IFNA1 IFNA2
12
Show member pathways
12.83 CDK6 FGF2 FGF4 IFNA1 IFNA2 IFNB1
13
Show member pathways
12.78 IFNA1 IFNA2 IFNB1 IL6 IRF7
14 12.77 FGF2 FGF4 KDR PDGFB TP53 VEGFA
15
Show member pathways
12.75 FGF2 FGF4 KDR PDGFB VEGFA
16 12.74 CDK6 FGF2 FGF4 IFNA1 IFNA2 IL6
17
Show member pathways
12.71 FGF2 FGF4 IL6 KDR PDGFB
18
Show member pathways
12.69 CDK6 FGF2 FGF4 IL6 KDR PDGFB
19
Show member pathways
12.6 CXCL1 FGF2 IL6 PDGFB TP53
20
Show member pathways
12.55 ICAM1 IFNA1 IFNA2 IFNB1 IRF7
21
Show member pathways
12.5 ALYREF CDK6 ICAM1 IFNA1 IFNA2 IFNB1
22
Show member pathways
12.43 IFNA1 IFNA2 IFNB1 IL6 IL6ST PDGFB
23
Show member pathways
12.41 FGF2 FGF4 IL6 KDR PDGFB
24
Show member pathways
12.4 FGF2 FGF4 KDR VEGFA
25 12.37 ICAM1 IL6 PDGFB TP53
26
Show member pathways
12.32 IFNA1 IFNA2 IFNB1 IL6
27 12.31 CCR8 CDK6 IL6ST IRF7 TP53
28 12.3 FGF2 KDR TP53 VEGFA
29
Show member pathways
12.26 CCR8 CDK6 CXCL1 FGF2 ICAM1 IFNA1
30 12.24 IFNA1 IFNA2 IFNB1 IL6
31 12.19 IFNA1 IFNA2 IFNB1 IRF7 TP53
32 12.12 ICAM1 KDR PDGFB TP53 VEGFA
33
Show member pathways
12.09 FGF2 FGF4 ICAM1 IL6 KDR PDGFB
34 12.08 FGF2 FGF4 IL6 KDR PDGFB VEGFA
35 12.03 CXCL1 ICAM1 IL6 TP53
36 11.99 FGF2 ICAM1 IL6 TP53 VEGFA
37 11.98 CXCL1 ICAM1 IFNB1 IL6
38 11.94 CXCL1 IFNB1 IL6 IL6ST IRF7 TP53
39 11.9 ICAM1 IL6 VEGFA
40 11.9 IFNA1 IFNA2 IFNB1 IL6 IL6ST
41
Show member pathways
11.89 CXCL1 ICAM1 IL6 IL6ST
42 11.88 CXCL1 ICAM1 IL6 VEGFA
43
Show member pathways
11.86 FGF2 FGF4 IFNA1 IFNA2 IFNB1 IL6
44 11.81 ICAM1 IL6 TP53
45 11.81 FGF2 FGF4 PDGFB VEGFA
46 11.76 IFNA2 IFNB1 IL6
47 11.67 FGF2 IL6 PDGFB
48
Show member pathways
11.67 ICAM1 IL6 VEGFA
49 11.57 IL6 TP53 VEGFA
50 11.55 FGF2 KDR VEGFA

GO Terms for Kaposi Sarcoma

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ADA2 CXCL1 FGF2 ICAM1 IFNA1 IFNA2
2 extracellular region GO:0005576 9.4 ADA2 CXCL1 FGF2 FGF4 IFNA1 IFNA2
3 interleukin-6 receptor complex GO:0005896 9.16 IL6 IL6ST

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.98 IFNA2 KDR PDGFB VEGFA
2 extracellular matrix organization GO:0030198 9.97 FGF2 ICAM1 KDR PDGFB
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 FGF2 FGF4 ICAM1 KDR PDGFB
4 positive regulation of cell proliferation GO:0008284 9.95 FGF2 FGF4 IL6 IL6ST KDR PDGFB
5 peptidyl-tyrosine phosphorylation GO:0018108 9.94 FGF2 FGF4 KDR PDGFB
6 defense response GO:0006952 9.91 CXCL1 IFNA1 IFNA2 IFNB1
7 defense response to virus GO:0051607 9.89 IFNA1 IFNA2 IFNB1 IL6 IRF7
8 B cell differentiation GO:0030183 9.85 IFNA1 IFNA2 IFNB1
9 positive regulation of MAP kinase activity GO:0043406 9.84 FGF2 PDGFB VEGFA
10 positive chemotaxis GO:0050918 9.8 FGF2 PDGFB VEGFA
11 positive regulation of endothelial cell proliferation GO:0001938 9.78 FGF2 KDR PDGFB VEGFA
12 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.77 FGF2 KDR VEGFA
13 B cell proliferation GO:0042100 9.76 IFNA1 IFNA2 IFNB1
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 IFNA2 IL6 IL6ST VEGFA
15 response to exogenous dsRNA GO:0043330 9.75 IFNA1 IFNA2 IFNB1
16 type I interferon signaling pathway GO:0060337 9.73 IFNA1 IFNA2 IFNB1 IRF7
17 T cell activation involved in immune response GO:0002286 9.72 IFNA1 IFNA2 IFNB1
18 cell migration involved in sprouting angiogenesis GO:0002042 9.71 FGF2 KDR VEGFA
19 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.7 IFNA1 IFNA2 IFNB1
20 interleukin-6-mediated signaling pathway GO:0070102 9.69 IL6 IL6ST
21 natural killer cell activation involved in immune response GO:0002323 9.69 IFNA1 IFNA2 IFNB1
22 positive regulation of DNA biosynthetic process GO:2000573 9.68 FGF2 PDGFB
23 positive regulation of acute inflammatory response GO:0002675 9.68 IL6 IL6ST
24 positive regulation of positive chemotaxis GO:0050927 9.68 KDR VEGFA
25 humoral immune response GO:0006959 9.67 IFNA1 IFNA2 IFNB1 IL6
26 paracrine signaling GO:0038001 9.65 FGF2 PDGFB
27 negative regulation of T cell differentiation GO:0045581 9.65 IFNA2 IFNB1
28 regulation of signaling receptor activity GO:0010469 9.65 ADA2 CXCL1 FGF2 FGF4 IFNA1 IFNA2
29 chondroblast differentiation GO:0060591 9.64 FGF2 FGF4
30 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.63 KDR VEGFA
31 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.62 IFNA2 IFNB1
32 positive regulation of blood vessel endothelial cell migration GO:0043536 9.62 FGF2 KDR PDGFB VEGFA
33 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.59 FGF2 FGF4
34 positive regulation of cell division GO:0051781 9.56 FGF2 FGF4 PDGFB VEGFA
35 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.55 ICAM1 IL6 PDGFB TP53 VEGFA
36 cytokine-mediated signaling pathway GO:0019221 9.32 CXCL1 FGF2 ICAM1 IFNA1 IFNA2 IFNB1
37 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 FGF2 FGF4 IFNB1 IL6 IRF7 TP53
38 multicellular organism development GO:0007275 10.2 ADA2 FGF2 FGF4 KDR PDGFB TP53
39 positive regulation of transcription, DNA-templated GO:0045893 10.1 FGF2 IFNA2 IL6 IRF7 PDGFB TP53
40 negative regulation of apoptotic process GO:0043066 10.08 FGF4 IL6 IL6ST KDR TP53 VEGFA
41 positive regulation of gene expression GO:0010628 10.06 FGF4 IL6 PDGFB TP53 VEGFA
42 viral process GO:0016032 10.03 ALYREF ICAM1 IL6ST IRF7 KDR TP53

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.67 ADA2 FGF2 FGF4 VEGFA
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 FGF2 FGF4 PDGFB
3 chemoattractant activity GO:0042056 9.5 FGF2 PDGFB VEGFA
4 cytokine activity GO:0005125 9.5 CXCL1 FGF2 IFNA1 IFNA2 IFNB1 IL6
5 platelet-derived growth factor receptor binding GO:0005161 9.46 PDGFB VEGFA
6 cytokine receptor binding GO:0005126 9.43 IFNA1 IFNA2 IFNB1
7 interleukin-6 receptor binding GO:0005138 9.4 IL6 IL6ST
8 type I interferon receptor binding GO:0005132 9.33 IFNA1 IFNA2 IFNB1
9 growth factor activity GO:0008083 9.17 ADA2 CXCL1 FGF2 FGF4 IL6 PDGFB

Sources for Kaposi Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....